[{"id":"9fd3bca0-1c10-442b-a00f-722b814378c6","acronym":"CD33 CAR NK","url":"https://clinicaltrials.gov/study/NCT07026942","created_at":"2025-06-21T13:17:33.882Z","updated_at":"2025-06-21T13:17:33.882Z","phase":"Phase 1/2","brief_title":"Phase I/II Clinical Trial Evaluating the Safety and Efficacy of Universal Donor CD33 CAR Natural Killer Cells for Treatment of Myeloid Leukemia","source_id_and_acronym":"NCT07026942 - CD33 CAR NK","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2031","primary_completion_date":" 07/01/2031","study_txt":" Completion: 07/01/2037","study_completion_date":" 07/01/2037","last_update_posted":"2025-06-18"},{"id":"1a1995ad-1100-4dcd-ab6d-59a84e130062","acronym":"","url":"https://clinicaltrials.gov/study/NCT03641755","created_at":"2021-01-18T17:52:39.950Z","updated_at":"2025-02-25T15:07:53.071Z","phase":"Phase 1","brief_title":"Olaparib + Sapacitabine in BRCA Mutant Breast Cancer","source_id_and_acronym":"NCT03641755","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • PGR positive","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • sapacitabine (CYC682)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-09-19"},{"id":"ee828508-f89b-44a7-a9da-155aa80b2469","acronym":"","url":"https://clinicaltrials.gov/study/NCT06520163","created_at":"2025-02-27T07:53:35.947Z","updated_at":"2025-02-27T07:53:35.947Z","phase":"Phase 3","brief_title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","source_id_and_acronym":"NCT06520163","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-25"},{"id":"b231ea21-7f7f-446d-8bf7-574330cb0835","acronym":"","url":"https://clinicaltrials.gov/study/NCT05536154","created_at":"2022-09-10T11:56:36.792Z","updated_at":"2024-07-02T16:35:14.036Z","phase":"","brief_title":"Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies","source_id_and_acronym":"NCT05536154","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-19"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"3c0f91c3-6211-41c1-8c32-6f8ec083190c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510089","created_at":"2022-08-22T13:04:16.199Z","updated_at":"2024-07-02T16:35:34.150Z","phase":"","brief_title":"Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies","source_id_and_acronym":"NCT05510089","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-10"},{"id":"859b9a56-0db0-49fc-bcaf-d9e45201f632","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415008","created_at":"2021-01-18T21:16:51.688Z","updated_at":"2024-07-02T16:35:34.633Z","phase":"Phase 2","brief_title":"Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT04415008","lead_sponsor":"wang, jianxiang","biomarkers":" CEBPA","pipe":" | ","alterations":" CEBPA mutation","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-05"},{"id":"2d6867ac-90da-4cfa-8f02-85cdea6ec075","acronym":"","url":"https://clinicaltrials.gov/study/NCT00516828","created_at":"2021-01-18T01:51:57.861Z","updated_at":"2025-02-25T17:15:17.128Z","phase":"Phase 1/2","brief_title":"Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT00516828","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/27/2007","start_date":" 11/27/2007","primary_txt":" Primary completion: 03/18/2010","primary_completion_date":" 03/18/2010","study_txt":" Completion: 01/10/2013","study_completion_date":" 01/10/2013","last_update_posted":"2023-08-04"},{"id":"400078f7-64d4-4277-9022-f03050a00674","acronym":"","url":"https://clinicaltrials.gov/study/NCT00840177","created_at":"2021-01-29T06:59:12.815Z","updated_at":"2024-07-02T16:35:49.076Z","phase":"Phase 2","brief_title":"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT00840177","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 12/10/2009","start_date":" 12/10/2009","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 10/21/2021","study_completion_date":" 10/21/2021","last_update_posted":"2023-05-03"},{"id":"7a766258-ef73-4c74-938d-a1a53533819e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04365933","created_at":"2021-01-18T21:05:55.917Z","updated_at":"2024-07-02T16:36:04.856Z","phase":"Phase 2a","brief_title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","source_id_and_acronym":"NCT04365933","lead_sponsor":"Enyo Pharma","biomarkers":" FGF19","pipe":"","alterations":" ","tags":["FGF19"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/25/2020","start_date":" 05/25/2020","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 11/29/2021","study_completion_date":" 11/29/2021","last_update_posted":"2022-08-25"},{"id":"44766fc1-3509-4938-9c77-565abb1837ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT02926586","created_at":"2021-01-18T14:22:28.719Z","updated_at":"2024-07-02T16:36:10.613Z","phase":"Phase 4","brief_title":"Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML","source_id_and_acronym":"NCT02926586","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" RUNX1 • RUNX1T1","pipe":"","alterations":" ","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 08/16/2020","primary_completion_date":" 08/16/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-05-11"},{"id":"7d0269ef-d62a-464e-b888-7fb2fa28d120","acronym":"","url":"https://clinicaltrials.gov/study/NCT05250362","created_at":"2022-02-22T13:52:32.086Z","updated_at":"2024-07-02T16:36:15.354Z","phase":"Phase 1/2","brief_title":"Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT05250362","lead_sponsor":"Sichuan University","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr del(7q)","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-03-15"},{"id":"c888a839-4434-4bf4-97af-0865b3e560f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00999401","created_at":"2021-01-18T03:54:26.432Z","updated_at":"2024-07-02T16:36:19.263Z","phase":"Phase 1","brief_title":"A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00999401","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapacitabine (CYC682) • seliciclib (CYC202)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 07/16/2019","primary_completion_date":" 07/16/2019","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2021-12-22"},{"id":"16804637-9fe5-4282-a88d-f5ffa656bdf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05123352","created_at":"2021-11-17T12:53:30.453Z","updated_at":"2024-07-02T16:36:20.639Z","phase":"","brief_title":"Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies","source_id_and_acronym":"NCT05123352","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2021-11-17"},{"id":"2500e33d-9ddb-4107-86af-158494807e91","acronym":"","url":"https://clinicaltrials.gov/study/NCT02144675","created_at":"2021-01-18T09:57:50.455Z","updated_at":"2024-07-02T16:36:25.924Z","phase":"Phase 2","brief_title":"Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT02144675","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 04/26/2016","primary_completion_date":" 04/26/2016","study_txt":" Completion: 04/26/2016","study_completion_date":" 04/26/2016","last_update_posted":"2021-08-24"},{"id":"cd2a2120-8206-4bc7-97e5-99651be9b52b","acronym":"Ara-C","url":"https://clinicaltrials.gov/study/NCT01191541","created_at":"2021-02-21T23:52:19.111Z","updated_at":"2024-07-02T16:36:26.660Z","phase":"Phase 4","brief_title":"Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)","source_id_and_acronym":"NCT01191541 - Ara-C","lead_sponsor":"Xiaofan Zhu","biomarkers":" RARA","pipe":"","alterations":" ","tags":["RARA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • arsenic trioxide"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2021-08-10"},{"id":"58ca73ff-c84e-4c36-8b48-77303f0651d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01627041","created_at":"2021-01-18T06:59:10.297Z","updated_at":"2024-07-02T16:36:28.861Z","phase":"Phase 2","brief_title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01627041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RARA • CBFB","pipe":"","alterations":" ","tags":["RARA • CBFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • decitabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 09/16/2011","start_date":" 09/16/2011","primary_txt":" Primary completion: 02/11/2016","primary_completion_date":" 02/11/2016","study_txt":"","study_completion_date":"","last_update_posted":"2021-06-21"},{"id":"31e64661-e7cd-458f-9157-198adacd1c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT01296178","created_at":"2021-01-18T05:16:00.306Z","updated_at":"2024-07-02T16:36:32.987Z","phase":"","brief_title":"PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years","source_id_and_acronym":"NCT01296178","lead_sponsor":"PETHEMA Foundation","biomarkers":" PML","pipe":"","alterations":" ","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-03-23"},{"id":"c9acec8c-0e67-476c-9285-256811a2ef31","acronym":"","url":"https://clinicaltrials.gov/study/NCT02046122","created_at":"2021-01-18T09:23:57.683Z","updated_at":"2024-07-02T16:36:37.907Z","phase":"Phase 1/2","brief_title":"Adoptive Transfer of Haplo-identical DLI for AML and MDS","source_id_and_acronym":"NCT02046122","lead_sponsor":"Duke University","biomarkers":" FLT3","pipe":" | ","alterations":" Chr del(5q)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 06/15/2017","primary_completion_date":" 06/15/2017","study_txt":" Completion: 07/31/2019","study_completion_date":" 07/31/2019","last_update_posted":"2020-12-03"},{"id":"fc61429b-02e4-47dd-8e39-d891112660b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01839240","created_at":"2021-01-18T08:11:28.225Z","updated_at":"2024-07-02T16:36:45.010Z","phase":"Phase 1","brief_title":"Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT01839240","lead_sponsor":"University of Chicago","biomarkers":" DCK","pipe":" | ","alterations":" TOP2A expression","tags":["DCK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TOP2A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/06/2012","start_date":" 06/06/2012","primary_txt":" Primary completion: 08/16/2019","primary_completion_date":" 08/16/2019","study_txt":" Completion: 08/16/2019","study_completion_date":" 08/16/2019","last_update_posted":"2020-05-15"},{"id":"5ff22ee6-6c95-4b3e-80e2-eb69bcdf6c52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01199562","created_at":"2021-01-18T04:48:21.624Z","updated_at":"2025-02-25T16:23:31.204Z","phase":"","brief_title":"Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","source_id_and_acronym":"NCT01199562","lead_sponsor":"City of Hope Medical Center","biomarkers":" NCAM1 • LAMP2","pipe":"","alterations":" ","tags":["NCAM1 • LAMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Valcyte (valganciclovir)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2019-04-25"},{"id":"f700ff55-4c3e-41aa-bed4-a08957a2e7f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03348033","created_at":"2021-01-18T16:32:01.857Z","updated_at":"2024-07-02T16:37:02.057Z","phase":"Phase 1/2","brief_title":"Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03348033","lead_sponsor":"Hospital de Clinicas de Porto Alegre","biomarkers":" IL21","pipe":"","alterations":" ","tags":["IL21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 5","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2019-03-12"},{"id":"38d3c83e-e1d4-4ec4-98e1-7268377b1ab9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642236","created_at":"2021-01-18T17:52:47.307Z","updated_at":"2024-07-02T16:37:07.598Z","phase":"Phase 2/3","brief_title":"Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML","source_id_and_acronym":"NCT03642236","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • sorafenib • cytarabine"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 122","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2018-08-22"},{"id":"9a0e103a-dc00-4713-b6a5-67367255e2f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01237808","created_at":"2021-01-18T04:58:56.068Z","updated_at":"2024-07-02T16:37:08.429Z","phase":"Phase 3","brief_title":"Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation","source_id_and_acronym":"NCT01237808","lead_sponsor":"University of Ulm","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV"],"overall_status":"Completed","enrollment":" Enrollment 144","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 07/13/2018","primary_completion_date":" 07/13/2018","study_txt":" Completion: 07/13/2018","study_completion_date":" 07/13/2018","last_update_posted":"2018-08-01"}]